{
  "note_id": "gold_t2dm_003",
  "scenario": "t2dm",
  "persona": "gold",
  "note_text": "**Clinical Note**\n\n**Patient Name:** Carlos Rodriguez  \n**Age:** 33 years  \n**Gender:** Male  \n**Occupation:** Restaurant Manager  \n**Date of Visit:** [Insert Date]  \n**BMI:** 32.4  \n\n**Chief Complaint:**  \nDiabetes follow-up.\n\n**History of Present Illness:**  \nCarlos Rodriguez is a 33-year-old male with a 3-year history of Type 2 Diabetes Mellitus, presenting for routine diabetes management. His last HbA1c, 3 months ago, was 8.5%, indicating uncontrolled diabetes. He reports home glucose readings of 160-220 mg/dL fasting and 180-250 mg/dL postprandial. He is currently on Metformin 1000mg twice daily with meals and reports occasional gastrointestinal upset but is tolerating the medication. He denies any episodes of hypoglycemia. He last had an eye exam 8 months ago, which showed no retinopathy, and a foot exam was performed today. He also has a history of hypertension, controlled on Lisinopril, and hyperlipidemia, managed with Atorvastatin. Lifestyle factors include a sedentary job with minimal exercise, struggles with portion control, and daily soda consumption. He denies polyuria, polydipsia, weight loss, and visual changes but reports occasional tingling in his feet. He also mentions occasional erectile dysfunction, which he suspects may be related to diabetes.\n\n**Review of Systems:**  \n- **General:** No fever, chills, or significant weight changes.  \n- **Eyes:** No visual changes reported.  \n- **Cardiovascular:** No chest pain or palpitations.  \n- **Respiratory:** No cough or dyspnea.  \n- **Gastrointestinal:** Occasional GI upset with Metformin, no nausea or vomiting.  \n- **Genitourinary:** Occasional erectile dysfunction.  \n- **Neurological:** Occasional tingling in feet, no headaches.  \n- **Endocrine:** No polyuria or polydipsia.  \n- **Dermatological:** No rashes or lesions.\n\n**Past Medical History:**  \n- Type 2 Diabetes Mellitus, diagnosed 3 years ago  \n- Hypertension  \n- Hyperlipidemia  \n\n**Medications:**  \n- Metformin 1000mg twice daily  \n- Lisinopril 20mg daily  \n- Atorvastatin 20mg daily  \n\n**Allergies:**  \n- No known drug allergies  \n\n**Social History:**  \n- Sedentary occupation as a restaurant manager.  \n- Minimal exercise, struggles with portion control, and consumes soda daily.  \n\n**Physical Examination:**  \n- **Vital Signs:** BP 128/78 mmHg, HR 78, Weight 185 lbs, Temperature 98.6\u00b0F  \n- **General:** Alert, obese, pleasant male.  \n- **Cardiovascular:** Regular rate and rhythm, no murmurs, peripheral pulses 2+ dorsalis pedis and posterior tibial bilaterally.  \n- **Respiratory:** Clear to auscultation bilaterally.  \n- **Extremities:** Monofilament test shows protective sensation intact bilaterally, skin intact without wounds or calluses, no edema, pedal pulses palpable.  \n- **Feet:** No deformities, nails trimmed, no fungal infection.\n\n**Assessment and Plan:**  \n1. **Type 2 Diabetes Mellitus, uncontrolled (ICD-10: E11.65)**  \n   - Add Semaglutide 0.25mg subcutaneous weekly, increase to 0.5mg after 4 weeks.  \n   - Continue Metformin 1000mg twice daily.  \n   - Order HbA1c in 3 months.  \n   - Referral to ophthalmology for an annual dilated eye exam (overdue).  \n   - Referral to diabetes educator for nutrition counseling.  \n   - Discussed lifestyle modifications: eliminate sugar-sweetened beverages, portion control, and increase physical activity to 150 min/week.  \n\n2. **Obesity (ICD-10: E66.9)**  \n   - Weight loss goal of 5-10% body weight over 6 months.  \n\n3. **Essential Hypertension, controlled (ICD-10: I10)**  \n   - Continue Lisinopril 20mg daily.  \n\n4. **Hyperlipidemia (ICD-10: E78.5)**  \n   - Continue Atorvastatin 20mg daily.  \n\n5. **Erectile Dysfunction**  \n   - Discussed possible relation to diabetes and vascular health. May consider PDE5 inhibitors if persistent.\n\n- **Vaccinations:** Ensure flu vaccine, check pneumococcal status.  \n- **Return visit:** In 6 weeks to assess tolerance and response to Semaglutide.  \n- **Patient education:** Glucose targets, HbA1c goal, lifestyle modifications, Semaglutide injection technique, and potential side effects.\n\n**Time Spent:** 25 minutes with extensive medication counseling and lifestyle education.  \n\n**Billing Level:** 99214 (Established patient, moderate to high complexity due to uncontrolled chronic disease).\n\n**Medical Decision Making:**  \nReviewed glycemic control with HbA1c 8.5%, above goal despite Metformin. Cardiovascular risk elevated due to diabetes, obesity, and age. Decision to add GLP-1 agonist for dual benefit of glucose control and weight loss, low hypoglycemia risk, and cardiovascular benefits. Addressed barriers to lifestyle change, including work schedule and dietary habits. Screening for complications is current except for ophthalmology (referral placed).",
  "demographics": {
    "age": 33,
    "gender": "M",
    "occupation": "restaurant manager",
    "name": "Carlos Rodriguez"
  },
  "generated_at": "2026-02-14T01:55:01.835635",
  "ground_truth_scores": {
    "completeness": 92,
    "accuracy": 95,
    "compliance": 90,
    "risk": 93,
    "clarity": 94
  }
}